Reviewed September 1, 2026
Regulatory, safety, and compliance evidence in one place
This dossier organizes high-confidence public records concerning Phenibut, with emphasis on United States regulatory treatment, documented toxicology, responsible labeling, and laboratory supply-chain controls. It is an educational research reference, not legal or medical advice.
FDA states that Phenibut does not meet the statutory definition of a dietary ingredient. It has also cited promotional claims as evidence of intended drug use.
WHO’s Expert Committee recommended continued surveillance rather than advancing Phenibut to critical review for international scheduling.
The national poison-center review covered reports from 2009–2019. The data are observational and do not establish a controlled incidence rate.
The Australian Poisons Standard places Phenibut in Schedule 9, with implementation occurring through Commonwealth, state, and territory frameworks.
A label does not operate in isolation. Product copy, category names, graphics, testimonials, social media, customer communications, and actual sales conduct can all inform how regulators evaluate intended use.
United States regulatory record
FDA’s Phenibut materials establish two distinct points. First, Phenibut is not a lawful dietary ingredient under the agency’s interpretation of the Federal Food, Drug, and Cosmetic Act. Second, presenting a product with claims about treating disease or affecting human structure or function can establish an intended drug use, regardless of whether another part of the page says “research use only.”
Dietary-supplement warning letters
FDA issued warning letters involving products labeled to contain Phenibut and publicly stated that the substance does not meet the definition of a dietary ingredient.
Phenibut claims examined directly
The Synaptent/LiftMode warning letter analyzed website and label claims for Phenibut HCl and Phenibut FAA when determining intended use.
Criminal enforcement record
Centera Bioscience and its CEO pleaded guilty to introducing misbranded drugs into interstate commerce. DOJ later reported probation, $2.4 million forfeiture, and surrender of seized products.
FDA consumer warning
FDA again described Phenibut as an unlawful dietary-supplement ingredient in an April 2026 alert concerning products marketed as supplements.
FDA: Phenibut in Dietary Supplements · FDA: Synaptent warning letter · DOJ: Centera sentencing record
International status requires country-level review
There is no single worldwide answer to Phenibut supply. WHO surveillance is not the same as authorization, approval, or legality in any particular country. National controls may be stricter and may distinguish possession, importation, analytical use, medical use, and commercial supply.
| Jurisdiction | High-confidence finding | Practical reading |
|---|---|---|
| United States | Not FDA-approved as a drug and not accepted by FDA as a dietary ingredient. | FDA status, intended-use evidence, federal scheduling, state law, import rules, and workplace requirements are separate questions. |
| Australia | Phenibut appears in Schedule 9 of the Poisons Standard. | Scientific or analytical activity may require specific authorization; local implementation must be checked. |
| United Kingdom | The Psychoactive Substances Act focuses on supply for human consumption for psychoactive effect. | Packaging, descriptions, business context, and retailer knowledge can be relevant to enforcement. |
| WHO | Phenibut remains on the ECDD surveillance list. | Surveillance is not a declaration that commerce is lawful in member countries. |
Verification rule: confirm the destination’s current rules immediately before offering, accepting, importing, or shipping an order. Historical statements should never be treated as a permanent legal conclusion.
Pharmacology: what the evidence supports
Phenibut is a structural analogue of GABA. Experimental literature supports activity at GABA-B receptors and binding at the α2δ subunit of voltage-dependent calcium channels, with stereoselective differences reported between enantiomers. That evidence belongs in a scientific reference context; it does not justify consumer-effect claims or instructions.
The human pharmacokinetic evidence base is limited. Frequently repeated claims about a precise elimination half-life or percentage excreted unchanged have a weak primary-source trail. They should not be presented as settled modern human pharmacokinetic specifications.
See the neutral Phenibut pharmacology overview, stereochemistry reference, and searchable literature index.
Toxicology and emergency information
CDC reviewed 1,320 Phenibut exposure reports made to United States poison centers from 2009 through 2019. Reported effects included agitation, drowsiness or lethargy, tachycardia, confusion, and coma. Major effects were recorded in 12.6% of reports, and three deaths were reported. These were poison-center reports rather than controlled clinical data, and exposure identity was not routinely laboratory-confirmed.
There is no scientifically established human lethal oral dose suitable for a label or product page. Animal LD50 values and individual case reports must not be converted into a predicted human fatal quantity.
In the United States, contact Poison Control at 1-800-222-1222. Call 911 for a medical emergency. This website does not provide individualized medical advice.
CDC MMWR: U.S. poison-center exposure reports
Packaging and label controls
Packaging should support containment, traceability, and accurate hazard communication. Net weight is a mass measurement; container volume must be selected through fill testing that accounts for bulk density, particle characteristics, and headspace. Tamper evidence and child resistance are separate packaging functions.
Identity
Match the chemical form, systematic name, CAS number, lot identifier, and net quantity to the material actually packaged.
Hazard classification
Do not invent signal words, pictograms, hazard codes, or precautionary statements. A qualified hazard classifier should establish them from the evidence.
Responsible party
Where OSHA Hazard Communication rules apply, shipped-container information can include the responsible party’s name, address, and telephone number.
Closure claims
Do not call a closure child-resistant merely because it uses a push-and-turn design. The claim should be supported by applicable performance testing.
OSHA Hazard Communication label elements · CPSC special-packaging FAQ
Lot-level quality file
A controlled research-material supply chain connects the source lot to every finished unit and shipment. The goal is to prevent mix-ups, preserve evidence, and make investigation or withdrawal possible.
- Supplier qualification, purchase order, commercial invoice, and source Certificate of Analysis
- Receiving, quarantine, sampling, test review, and release records
- Controlled SDS and hazard-classification rationale
- Packaging components, unit reconciliation, label revision, and retain sample
- Complaint, exposure, investigation, withdrawal, and recall procedures
Continue with quality and documentation standards, Certificate of Analysis guidance, and Safety Data Sheet guidance.
Authoritative source desk
CDCPoison-center exposure surveillance
WHOECDD substances under surveillance
AustraliaJune 2026 Poisons Standard
UK Home OfficeRetailer guidance
OSHAHazard Communication Standard
Scope and limitations
This page summarizes selected public records as of September 1, 2026. It does not establish that any particular transaction is lawful or suitable. Laws, schedules, authorizations, product classifications, and agency interpretations can change. Obtain qualified legal, regulatory, toxicological, and hazard-communication review for the actual material, claims, packaging, destination, and customer.